Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-28
2011-06-28
Andres, Janet (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S204000, C548S504000, C514S332000, C514S365000, C514S426000
Reexamination Certificate
active
07968723
ABSTRACT:
Novel compounds of the general formula (I), in which the variables are as defined in claim1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.
REFERENCES:
patent: 4920132 (1990-04-01), Huang et al.
patent: 5324743 (1994-06-01), Dillard et al.
patent: 5538768 (1996-07-01), Marden et al.
patent: 6448293 (2002-09-01), Andrews et al.
patent: 6525094 (2003-02-01), Zhang et al.
patent: 6630504 (2003-10-01), Andrews et al.
patent: 6869975 (2005-02-01), Abe et al.
patent: 6875780 (2005-04-01), Auerbach et al.
patent: 6939875 (2005-09-01), Auerbach et al.
patent: 6964983 (2005-11-01), Auerbach et al.
patent: 7244763 (2007-07-01), Bratton et al.
patent: 7816385 (2010-10-01), Sauerberg et al.
patent: 2001/0041709 (2001-11-01), Mogensen et al.
patent: 2004/0192743 (2004-09-01), Mjalli et al.
patent: 2004/0209936 (2004-10-01), Bratton et al.
patent: 2005/0113440 (2005-05-01), Auerbach et al.
patent: 2007/0082907 (2007-04-01), Canada et al.
patent: 2009/0048257 (2009-02-01), Sauerberg et al.
patent: 2009/0192162 (2009-07-01), Ebdrup
patent: 2279659 (1995-01-01), None
patent: 2003-171275 (2003-06-01), None
patent: 97/27847 (1997-08-01), None
patent: 97/27857 (1997-08-01), None
patent: 97/28115 (1997-08-01), None
patent: 97/28137 (1997-08-01), None
patent: 97/28149 (1997-08-01), None
patent: 98/27974 (1998-07-01), None
patent: 99/04815 (1999-02-01), None
patent: WO 99/20275 (1999-04-01), None
patent: 01/00603 (2001-01-01), None
patent: 01/25181 (2001-04-01), None
patent: WO 01/25226 (2001-04-01), None
patent: WO 02/28434 (2001-04-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34200 (2001-05-01), None
patent: WO 01/60807 (2001-08-01), None
patent: WO 01/66098 (2001-09-01), None
patent: 01/79197 (2001-10-01), None
patent: 02/14291 (2002-02-01), None
patent: 02/46154 (2002-06-01), None
patent: WO 02/50048 (2002-06-01), None
patent: WO 02/053547 (2002-07-01), None
patent: 02/59098 (2002-08-01), None
patent: WO 02/062774 (2002-08-01), None
patent: WO 02/070011 (2002-09-01), None
patent: 02/076957 (2002-10-01), None
patent: 02/079162 (2002-10-01), None
patent: 02/080899 (2002-10-01), None
patent: 02/098840 (2002-12-01), None
patent: 02/100812 (2002-12-01), None
patent: WO 03/002081 (2003-01-01), None
patent: 03/016265 (2003-02-01), None
patent: 03/016291 (2003-02-01), None
patent: WO 03/024395 (2003-03-01), None
patent: 03/033493 (2003-04-01), None
patent: WO 03/033453 (2003-04-01), None
patent: 03/035603 (2003-05-01), None
patent: 03/072100 (2003-09-01), None
patent: 03/074050 (2003-09-01), None
patent: 03/074051 (2003-09-01), None
patent: 03/074052 (2003-09-01), None
patent: WO 03/074495 (2003-09-01), None
patent: 03/084916 (2003-10-01), None
patent: 2003/084916 (2003-10-01), None
patent: 03/097607 (2003-11-01), None
patent: WO 2004/000315 (2003-12-01), None
patent: WO 2004/000762 (2003-12-01), None
patent: 2004/005253 (2004-01-01), None
patent: WO 2004/007439 (2004-01-01), None
patent: 2004/022533 (2004-03-01), None
patent: 2004/056740 (2004-07-01), None
patent: WO 2004/060871 (2004-07-01), None
patent: WO 2004/063165 (2004-07-01), None
patent: WO 2004/063166 (2004-07-01), None
patent: 2004/071447 (2004-08-01), None
patent: WO 2004/073606 (2004-09-01), None
patent: WO 2004/080943 (2004-09-01), None
patent: WO 2004/080947 (2004-09-01), None
patent: WO 2004/092117 (2004-10-01), None
patent: WO 2004/093879 (2004-11-01), None
patent: WO 2004/099170 (2004-11-01), None
patent: WO 2005/054176 (2005-06-01), None
patent: WO 2005/097098 (2005-10-01), None
patent: WO 2005/097762 (2005-10-01), None
patent: WO 2005/097763 (2005-10-01), None
patent: WO 2005/113506 (2005-12-01), None
patent: 2007/003581 (2007-01-01), None
patent: WO 2007/003581 (2007-01-01), None
patent: 2007/101864 (2007-09-01), None
Schiffrin et. al., “Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension”, Hypertension, 2003, 42; pp. 664-668.
Chilonczyk et. al., “Hypolipidaemic and antiplatelet agents”, 2001, Expert Opin. Ther. Patents, 11 (8), pp. 1301-1327.
Berger, J et al—The J of Biological Chem—1999—vol. 274—Part 10—pp. 6718-6725.
Leibowitz. M.D. et al—F E B S Lett—2000—vol. 473—pp. 333-336.
Oliver. W.R. et al—PNAS—2001—vol. 98—Part 9—pp. 5306-5311.
Muoio. D.M. et al—The J of Biological Chem—2002—vol. 277—Part 29-pp. 26089-26097.
Wang. Y-X et al—Cell—2003—vol. 113—pp. 159-170.
Luquet. S et al—Faseh J—2003—vol. 17—Part 13—pp. 209-226.
Tanaka. T et al—PNAS—2003—vol. 100—Part 26—pp. 15924-15929.
Holst, D et al—Biochem Biophys Acta—2003—vol. 1633 —pp. 43-50.
Dressel, U et al—Mol Endocrinol—2003—vol. 17—Part 12—pp. 2477-2493.
Lee, C-H et al—Science—2003—vol. 32—pp. 453-457.
International Search Report for PCT/EP05/052014, dated Sep. 16, 2005.
International Preliminary Report on Patentability for PCT/EP05/052014, dated Nov. 16, 2006.
Berger, J. and Wagner, J., “Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors,” Diabetes Technology & Therapeutics, vol. 4(2), pp. 163-174 (2002).
Colagiuri et al., American Journal of Public Health, Sep. 2006, vol. 96, No. 9, pp. 1562-1569.
Curtis et al., The Journal of the American Board of Family Practice, vol. 18, pp. 37-43, (2005).
Epple et al., Bioorganic & Medicinal Chemistry Letters 2006, 16, 4376-4380.
Everett, L., et al., “The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease,” Liver, vol. 20, pp. 191-199 (2000).
Fruchart, J., “PPAR and Cardiovascular Risk: Overview,” J. Cardiovasc. Risk, vol. 8(4), pp. 185-186 (Aug. 2001).
Golub et al., Science, vol. 286, Oct. 15, 1999, pp. 531-537.
Gross et al., Best Practice & Research Clinical Endocrinology & Metabolism 2007, 21, 687-710.
Havranek et al., “E/Z Isomerization of 3,3-disubstituted allylic thioethers” Tetrahedron Lett., vol. 48,. pp. 6970-6973 (2007).
Hussain et al., Diabetes Research and Clinical Practice 2007, 76, 317-326.
Jones, B., “Peroxisome Proliferative-Activated Receptor (PPAR) Modulators: Diabetes and Beyond,” Medicinal Research Reviews, vol. 21(6), pp. 540-552 (Nov. 2001).
Kaplan, F., et al., “PPARs, Insulin Resistance and Type 2 Diabetes,” J. Cardiovasc. Risk, vol. 8(4), pp. 211-217 (Aug. 2001).
Kersten, S., et al., “Roles of PPARs in health and disease,” Nature, vol. 405, pp. 421-424 (May 2000).
Landreth et al., Neurobiology of Aging, 2001, 22, 937-944.
Lee, C.H. et al., “PPAR-delta regulates glucose metabolism and insulin sensitivity”, Proceedings of the National Academy of Sciences of the USA, 2006, vol. 103, No. 9, pp. 3444-3449.
Liu, K., et al., “Identification of a Series of PPAR gamma/delta Dual Agonists via Solid-Phase Parallel Synthesis,” Bioorg. Med. Chem. Lett., vol. 11, pp. 2959-2962 (Nov. 2001).
Michalik, L., and Wahli, W., “Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions,” Curr. Opin. Biotechnology, vol. 10, pp. 564-570 (1999).
Miller, A., and Etgen, G., “Novel peroxisome proliferator-activated receptor ligands for type 2 diabetes and the metabolic syndrome,” Expert Opin. Inve
Ebdrup Soren
Havranek Miroslav
Pettersson Ingrid
Pihera Pavel
Sauerberg Per
Andres Janet
Dailey Robert S.
High Point Pharmaceuticals, LLC
Reese Heidi
LandOfFree
Compounds, their preparation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, their preparation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, their preparation and use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684319